Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48 + tislelizumab after maximal TURBT for bladder-preserving treatment of muscle-invasive bladder cancer
ChiCTR2400080073Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and tislelizumab in bladder cancer and transitional cell carcinoma of the bladder (TCC), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Clinical complete response rate. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
disitamab vedotintislelizumab
03
Conditions
bladder cancertransitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2400080073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080073.